Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 12,567 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director owned 124,557 shares in the company, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $33.03 on Thursday. The firm has a market cap of $2.13 billion, a P/E ratio of -9.89 and a beta of 1.20. Stoke Therapeutics, Inc. has a fifty-two week low of $18.00 and a fifty-two week high of $40.22. The firm has a 50-day simple moving average of $30.90 and a two-hundred day simple moving average of $32.23.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -3.5 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on STOK shares. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. The Goldman Sachs Group assumed coverage on Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price target on the stock. Wedbush increased their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, Guggenheim reissued a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.00.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. BlackRock Inc. bought a new position in shares of Stoke Therapeutics in the second quarter worth approximately $192,307,000. RTW Investments LP raised its position in shares of Stoke Therapeutics by 8.3% during the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after purchasing an additional 423,331 shares during the period. Redmile Group LLC raised its position in shares of Stoke Therapeutics by 3.2% during the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after purchasing an additional 130,050 shares during the period. Morgan Stanley lifted its stake in shares of Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after buying an additional 9,108 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Stoke Therapeutics by 13.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after buying an additional 423,601 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.